ReviewJournal of medical genetics2004
BRCA1 functions as a breast stem cell regulator.
Review in Journal of medical genetics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 185 citations in OpenAlex.
- Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Clinicopathological Characteristics of Lesions Diagnosed by MRI-Guided Biopsy inEuropean journal of breast health · 2026Article
- Targeting Key Molecular Mechanisms in Triple-Negative Breast Cancer Therapies with Natural Compounds.Current pharmaceutical design · 2026Review
- Innate Immune Program in Formation of Tumor-Initiating Cells from Cells-of-Origin of Breast, Prostate, and Ovarian Cancers.Cancers · 2023Review
- Distinct niche structures and intrinsic programs of fallopian tube and ovarian surface epithelial cells.iScience · 2023Article
- The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.Antioxidants (Basel, Switzerland) · 2022Review
- Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation.Nature communications · 2022Article
- Cell-type-specific epigenomic variations associated withNAR genomics and bioinformatics · 2022Article
- PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.Breast cancer research : BCR · 2021Article
- The Unique Genetic and Histological Characteristics of DMBA-Induced Mammary Tumors in an Organoid-Based Carcinogenesis Model.Frontiers in genetics · 2021Article
- p63 at the Crossroads between Stemness and Metastasis in Breast Cancer.International journal of molecular sciences · 2019Review
- Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.Scientific reports · 2017Article
- p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.Oncotarget · 2016Article
- Cellular, physiological and pathological aspects of the long non-coding RNA NEAT1.Frontiers in biology · 2016Article
- Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.Oncotarget · 2016Article
- Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.Oncogene · 2016Article
- Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.Breast cancer research : BCR · 2016Article
- BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.Cell cycle (Georgetown, Tex.) · 2016Review
- The origin of breast tumor heterogeneity.Oncogene · 2015Review
- Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRCA1 is an important susceptibility gene for breast cancer, which confers substantial lifetime risks of breast cancer, particularly in the pre-menopausal age group. Typically, carriers of BRCA1 mutations develop breast tumours that grow rapidly and are high grade and oestrogen receptor negative. They also possess a basal epithelial phenotype, as defined by cytokeratin expression, that is not present in most breast cancers. It has recently been proposed that the adult breast stem cell expresses only basal keratins. Others have indicated a CD44 positive, CD24 negative phenotype for breast cancer stem cells. In this paper, I argue that the biology of human BRCA1 and its rodent homologues and the clinicopathological features of breast cancer related to BRCA1 support the notion that one of the key functions of BRCA1 is to act as a stem cell regulator. This has implications for the management of carriers of mutations of BRCA1, in part because support for the role of BRCA1 as a stem cell regulator would emphasise the distinct nature of breast cancer related to BRCA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.